"NIH Trials Fall Short in Testing Effective Long Covid Treatments, Despite $1 Billion Investment"

Clinical trials for long Covid, funded by a $1 billion mandate from Congress to the National Institutes of Health (NIH), have finally been launched after 2.5 years. However, scientists and patients are skeptical that these trials will deliver meaningful treatments, as they primarily focus on observational research rather than addressing the underlying biological issues of long Covid. Concerns have also been raised about the trial designs and measurement methods, potentially leading to missed positive impacts or harmful side effects. Patients and experts argue that the NIH's efforts have been underwhelming and that additional funding and more innovative research approaches are needed to find effective treatments for long Covid.